Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer

This trial is a prospective, single-arm, multi-center clinical trial designed to assess whether adaptive radiotherapy with urethral sparing for low to intermediate risk localized prostate cancer will translate into a decreased rate of patient reported acute urinary side effects, as measured by the patient reported EPIC-26 questionnaire, compared with the historically reported rate for non-adaptive, non-urethral sparing prostate SBRT.

Trial Details

NCT ID
NCT05804318
Phase
NA
Sponsor
Varian, a Siemens Healthineers Company
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Daily adaptive SBRT with urethral sparing
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Irvine, California, United States|33.66946,-117.82311
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • St Louis, Missouri, United States|38.62727,-90.19789
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362

Key Eligibility Criteria

  • Patient has NCCN low or intermediate risk prostate cancer that is biopsy proven.
  • Prostate volume is ≤80cc as assessed by MRI prior to radiotherapy.
  • AUA/IPSS score is ≤ 15.
  • ECOG performance status is ≤2 (or Karnofsky score is ≥60%).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →